Processa Pharmaceuticals’ (PCSA) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Processa Pharmaceuticals (NASDAQ:PCSA) in a research note published on Thursday morning,Benzinga reports. They currently have a $6.00 price objective on the stock.

Processa Pharmaceuticals Trading Up 1.0 %

PCSA stock opened at $1.03 on Thursday. Processa Pharmaceuticals has a 1-year low of $0.85 and a 1-year high of $17.40. The stock’s fifty day simple moving average is $1.17 and its two-hundred day simple moving average is $1.49. The stock has a market cap of $3.35 million, a P/E ratio of -0.29 and a beta of 0.66.

About Processa Pharmaceuticals

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.